GlassScriptPhysician profile
Ruben Garcia
NPI 1639265846
$4,023.54
in general payments reported to CMS, 2019-2025
25 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $939 · 2021: $755 · 2022: $315 · 2023: $690 · 2024: $405 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $808.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $707.75 | 2021-2025 | |
| Glaxosmithkline, LLC. | $381.37 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $279.87 | 2019-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $219.22 | 2019-2024 | |
| Allergan, INC. | $216.42 | 2019-2020 | |
| Pfizer INC. | $209.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $191.83 | 2020-2024 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.45 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $176.68 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.42 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $94.66 | 2019-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $70.94 | 2019-2020 | |
| Axsome Therapeutics, INC. | $51.50 | 2022-2024 | Auvelity |
| Corcept Therapeutics | $49.95 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $48.81 | 2023 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $37.96 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $31.86 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $29.93 | 2021 | |
| Amgen INC. | $29.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.62 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.41 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $13.80 | 2023 | Inpefa |
| Nestle Healthcare Nutrition INC. | $13.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.